The technology, which is still in the research and development phase, allows for “for more precise 3D visualization of different tissues and contrast agents by capturing X-rays at multiple energy levels simultaneously,” according to a Feb. 25 news release from the university.
“This could improve cancer detection,” study author Mini Das, PhD, a professor at the University of Houston, said in the release. “If you inject two different contrast agents — one targeting a tumor and another targeting inflammation — you could see where each one accumulates.”
Read the full study here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.